577 related articles for article (PubMed ID: 20660959)
1. Biological markers in lung cancer: A clinician's perspective.
Tufman A; Huber RM
Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
[TBL] [Abstract][Full Text] [Related]
2. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?
Bremnes RM; Sirera R; Camps C
Lung Cancer; 2005 Jul; 49(1):1-12. PubMed ID: 15949585
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
7. The 'Sentinel Node' Concept: More Questions Raised than Answers Provided?
Schlag PM
Oncologist; 1998; 3(5):VI-VII. PubMed ID: 10388128
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
Milas I; Komaki R; Hachiya T; Bubb RS; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
Clin Cancer Res; 2003 Mar; 9(3):1070-6. PubMed ID: 12631609
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
10. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
11. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
13. Clinical detection of lung cancer progression markers.
Tockman MS
J Cell Biochem Suppl; 1996; 25():177-84. PubMed ID: 9027616
[TBL] [Abstract][Full Text] [Related]
14. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
15. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment.
Hsu HS; Chen TP; Wen CK; Hung CH; Chen CY; Chen JT; Wang YC
J Pathol; 2007 Dec; 213(4):412-9. PubMed ID: 17973238
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data.
Mountzios G; Dimopoulos MA; Soria JC; Sanoudou D; Papadimitriou CA
Crit Rev Oncol Hematol; 2010 Aug; 75(2):94-109. PubMed ID: 19914087
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.
O'Flaherty JD; Gray S; Richard D; Fennell D; O'Leary JJ; Blackhall FH; O'Byrne KJ
Lung Cancer; 2012 Apr; 76(1):19-25. PubMed ID: 22209049
[TBL] [Abstract][Full Text] [Related]
18. Early detection of lung cancers - Comparison of computed tomography, cytology and fuzzy-based tumor markers panels.
Schneider J
Cancer Biomark; 2010; 6(3-4):149-62. PubMed ID: 20660961
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of biomarkers in advanced non-small-cell lung cancer.
Socinski MA
Clin Lung Cancer; 2010 May; 11(3):149-59. PubMed ID: 20439190
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer.
Carpagnano GE; Foschino-Barbaro MP; Resta O; Gramiccioni E; Carpagnano F
Oncology; 2004; 66(3):180-4. PubMed ID: 15218307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]